TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03993457

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion
Description: Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion
Description: Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
Study: NCT01117129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000 mg by i.v. infusion on day 1 and 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: i.v. infusion on day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25 mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: 10-25 mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [Mabthera/Rituxan]
Description: 1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab [Mabthera/Rituxan]
Description: 1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
Study: NCT03939481

Intervention type: DRUG
Intervention: Chemotherapy
Description: Given chemotherapy regimen

Intervention type: OTHER
Intervention: Functional Assessment
Description: Functional and sensory clinician assessments

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Patient and physician reported responses
Study: NCT03182296

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT
Study: NCT04902599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renuvion/j-Plasma procedure using blunt dissection technique
Description: Renuvion/j-Plasma procedure using blunt dissection technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renuvion/j-Plasma procedure using ultrasound-guided dissection technique
Description: Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
Study: NCT03701633

Intervention type: DIAGNOSTIC_TEST
Intervention: Postpartum ultrasound
Description: Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.

Intervention type: DIAGNOSTIC_TEST
Intervention: Postpartum ultrasound
Description: Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
Study: NCT01852188

Intervention type: OTHER
Group type: OTHER
Intervention: Type of glove used for intrapartum vaginal exams
Description: Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.

Intervention type: OTHER
Group type: OTHER
Intervention: Type of glove used for intrapartum vaginal exams
Description: Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
Study: NCT03234712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-321
Description: Intravenous infusion
Study: NCT01441583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAAT
Description: For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RAAT
Description: For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RAAT
Description: For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RYTHMIQ
Description: For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RYTHMIQ
Description: For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
Study: NCT03082898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Exoskeleton
Description: Regular dosing of Indego Exoskeleton walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Exoskeleton
Description: Regular dosing of Indego Exoskeleton walking.
Study: NCT04517968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant with customized healing abutment
Description: * All patients will be operated under local anesthesia.~* Atraumatic extraction of the remaining root or tooth will be achieved.~* A careful curettage of the socket will be performed if any granulation tissue is present.~* Sequential drilling of the osteotomy site with copious irrigation will be done~* The Implant is secured in place using a torque wrench.~* Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~* Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~* The abutment will be attached to the implant.
Study: NCT02080390

Intervention type: PROCEDURE
Intervention: Transthoracic echocardiogram (ultrasound)
Description: Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
Study: NCT01688817

Intervention type: OTHER
Group type: OTHER
Intervention: Physician's counseling
Description: Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information leaflet
Description: Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
Study: NCT02449057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUST
Description: Swift, certain, and proportionate sanctions for violations of terms of community supervision.
Study: NCT04211025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modest
Description: The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive
Description: The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
Study: NCT05656612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written, Oral and Visual Education
Description: Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written, Oral and Visual Education
Description: Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written, Oral and Visual Education
Description: Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
Study: NCT00559377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Undergo \^18F FMISO PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F 18
Description: Undergo \^18F FDG PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo \^18F-FMISO and \^18F FDG PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tissue oxygen measurement
Description: Undergo \^18 F FMISO PET and \^18F FDG PET
Study: NCT02020746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Study: NCT05142579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDOTRAKEAL TUBE HOLDER
Description: During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BANDAGE
Description: On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
Study: NCT02205294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Treatment
Description: The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
Study: NCT01734590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate based food mix 1
Description: Carbohydrate based food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate based food mix 1
Description: Carbohydrate based food

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate based food mix 2
Description: Carbohydrate based food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate based food mix 2
Description: Carbohydrate based food

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control carbohydrate based food
Description: Carbohydrate based food

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control carbohydrate based food
Description: Carbohydrate based food
Study: NCT01937585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner and CDC brochure condition
Description: Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC brochure only condition
Description: Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
Study: NCT00839787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
Study: NCT02148315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: garden
Study: NCT00808470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-carotene, vitamins C and E, magnesium
Description: 6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene.
Study: NCT01777126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Protocol (ONP) group
Description: For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
Study: NCT00808470

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
Study: NCT00619125

Intervention type: OTHER
Intervention: palm pilot recording responses to questionnaires
Description: Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.

Intervention type: OTHER
Intervention: palm pilot recording responses to questionnaires
Description: Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.

Intervention type: OTHER
Intervention: palm pilot recording responses to questionnaires
Description: Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
Study: NCT03690362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 and VNRX-5022
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 and VNRX-5022
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 and VNRX-5022
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 and VNRX-5022
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 and VNRX-5022
Description: intravenous infusion
Study: NCT02682511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ifetroban
Description: Subjects will be treated with oral ifetroban or placebo daily for 365 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ifetroban
Description: Subjects will be treated with oral ifetroban or placebo daily for 365 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Subjects will be treated with oral ifetroban or placebo daily for 365 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Subjects will be treated with oral ifetroban or placebo daily for 365 days
Study: NCT02324621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ONC201
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00893971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001
Description: Inhaled PT001, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005
Description: Inhaled PT005, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: Inhaled PT003, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 + PT005
Description: Inhaled PT001 + PT005, single dose
Study: NCT03151213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg before RFA of liver cancer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo before RFA of liver cancer
Study: NCT04691687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: IV loop diuretic therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Solution
Description: IV Placebo comparator
Study: NCT00978341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150mg capsules BID for 7.5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for pregabalin
Description: Placebo capsules BID for 7.5 days
Study: NCT04888858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)
Description: As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
Study: NCT04455737

Intervention type: OTHER
Intervention: injection of indigo carmine
Description: Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
Study: NCT04063722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Benelli procedure
Description: use of modified Benelli procedure for surgical treatment of gynecomastia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Benelli procedure
Description: use of modified Benelli procedure for surgical treatment of gynecomastia
Study: NCT02259829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study: NCT03099226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo blue hard gelatine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo blue hard gelatine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)